Senate Infrastructure Legislation ‘Pay Fors’ Not So Bad For Pharma But Real Threat is Ahead

Senate negotiators opt to delay but not withdraw the pharma-backed rebate rule and target a relatively small reform aimed at allowing Medicare Part B to recoup the cost of leftover physician-administered drugs